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(27.8%) were protein bound. Most of them had a molecularReview on uremic toxins: Classification, concentration, and
weight 500 D except for leptin and retinol-binding protein.interindividual variability.
The ratio CU/CN, an index of the concentration range over whichBackground. The choice of the correct concentration of po-
toxicity is exerted, exceeded 15 in the case of 20 compounds. Thetential uremic toxins for in vitro, ex vivo, and in vivo experi-
highest values were registered for several guanidines, protein-ments remains a major area of concern; errors at this level might
bound compounds, and middle molecules, to a large extentresult in incorrect decisions regarding therpeutic correction of
compounds with known toxicity. A ratio of CMAX/CU 4, point-uremia and related clinical complications.
ing to a Gaussian distribution, was found for the majority ofMethods. An encyclopedic list of uremic retention solutes
the compounds (74/90; 82%). For some compounds, however,was composed, containing their mean normal concentration
this ratio largely exceeded 4 [e.g., for leptin (6.81) or indole-(CN), their highest mean/median uremic concentration (CU),
3-acetic acid (10.37)], pointing to other influencing factors thantheir highest concentration ever reported in uremia (CMAX),
renal function, such as gender, genetic predisposition, proteo-and their molecular weight. A literature search of 857 publica-
lytic breakdown, posttranslation modification, general condi-tions on uremic toxicity resulted in the selection of data re-
tion, or nutritional status.ported in 55 publications on 90 compounds, published between
Conclusion. Concentrations of retention solutes in uremia1968 and 2002.
vary over a broad range, from nanograms per liter to grams perResults. For all compounds, CU and/or CMAX exceeded CN.
liter. Low concentrations are found especially for the middleMolecular weight was lower than 500 D for 68 compounds; of
molecules. A substantial number of molecules are proteinthe remaining 22 middle molecules, 12 exceeded 12,000 D. CU
bound and/or middle molecules, and many of these exert toxic-ranged from 32.0 ng/L (methionine-enkephalin) up to 2.3 g/L
ity and are characterized by a high range of toxic over normal(urea). CU in the ng/L range was found especially for the middle
concentration (CU/CN ratio). Hence, uremic retention is a com-molecules (10/22; 45.5%), compared with 2/68 (2.9%) for a
plex problem that concerns many more solutes than the currentmolecular weight 500 D (P  0.002). Twenty-five solutes
markers of urea and creatinine alone. This list provides a basis
for systematic analytic approaches to map the relative impor-
tance of the enlisted families of toxins.Key words: uremic toxins, uremic toxicity, renal failure, concentrations,
retention.
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[1–3]. These compounds are called uremic retention sol- single uremic concentration. Subsequently, 55 publica-
tions were used for the present analysis.utes, or uremic toxins, when they interact negatively with
Compounds were included only if their mean/medianbiologic functions.
uremic concentration and/or maximum uremic concentra-A substantial number of publications have been de-
tion were in excess of the reported normal concentration.voted to the concentration changes of individual uremic
For the sake of uniformity, all concentration (C) valuesretention solutes in several conditions of end-stage renal
were normalized to a volume of 1 liter (L), and weredisease (ESRD). To our knowledge, no attempts have
reported in grams per liter (g/L), or, if less concentrated,been made, however, to develop an in depth and system-
in milligrams per liter (mg/L), micrograms per liter (g/L),atic overview of all these data with the intention to open
or nanograms per liter (ng/L). Data that were reportedthe field for new analytic approaches.
in mole per liter (mol/L) or equivalent units were trans-Various aspects of the uremic syndrome remain partly
formed to g/L or equivalent concentration values by theor entirely unexplored, although an exact knowledge of
formula:its nature, as well as of the relative importance of the
various responsible toxins, is urgently needed to allow C (g/L)  [C (mol/L)  molecular weight] (Eq. 1)
the development of better defined and more specific
Units of concentration were chosen in a way that theremoval strategies than the empiric ones based on diffu-
uremic concentration always exceeded 1.0. All data weresion, convection, or molecular size exclusion, as applied
reported up to one digit below unity, unless if normalin the current dialysis membranes today. The clinical
values or their standard deviations (SD) were smallerimportance to address this issue in depth has recently
than 0.1. The molecular weights utilized might be slightlybeen stressed by the demonstration of an improved out-
different from other reported values, depending on thecome when clearance of uremic toxins with a molecular
methods and procedures applied to identify the molecu-weight range of approximately 1000 to 5000 D was en-
lar size [i.e., sodium dodecyl sulfate (SDS)-gel electro-hanced [4].
phoresis, gel permeation chromatography, mass spec-In many studies, concentrations are applied that ex-
troscopy, or others].ceed those encountered in uremia, so that conclusions
Uremic concentrations were all expressed as mean might have relatively little clinical relevance. To over-
SD, or if means were lacking, as median. If literature
come these pitfalls, in the present publication, three lists data were expressed in mean  SEM, SEM was trans-
are presented containing in total 90 retention solutes formed to SD according to the formula:
together with their normal and uremic concentrations,
SD  SEM  (n 1) (Eq. 2)offering a “dictionary” of uremic retention solutes, in a
standardized and homogeneous manner. The work has Our primary research was aimed at finding the highest
been constructed as an objective report of the available reported mean/median uremic concentrations (CU). These
information, rather than as a critical analysis of how this values were noted, regardless of whether the patients re-
information has been obtained. The report is followed ported were in the predialytic stage, or dialysed by hemo-
by a number of reflections regarding the characteristics dialysis or peritoneal dialysis. If possible, the correspond-
and the retention pattern of the depicted molecules. The ing normal values (CN) were extracted from the same
aim is to offer a platform for more systematic future publications. If not available in these specific publica-
studies in the area of uremic toxicity. tions, normal values were collected from other sources.
If normal values were indicated in the publications as
being below a given detection limit, this limit was intro-METHODS
duced as the highest normal value. If normal values were
A database of 857 publications, published between given as a range, also the highest value was taken as the
1966 and 2002, covering the field of uremic toxins and/or reference. In both cases, the normal value is accompa-
uremic toxicity, was considered. The references were nied by the symbol “” in the tables. In any other case,
collected based on a Medline literature search (Refer- means  SD are given and the means were taken as the
ence Manager 9) with as reference words (search items) reference value. Per CN, CU, or CMAX value, only one lit-
“uremic toxins/uremic toxicity” and/or specific names of erature reference was finally to be used for data collec-
known retention solutes as recently reviewed [1, 3, 5]. tion, so that per molecule maximum three references
This list was further completed based on the personal can be found. It, however, occurred only once that we had
expertise of the authors. Among these publications, 149 to refer to three publications (homocysteine), whereas
were devoted to solute concentration. Only plasma/serum the characteristic concentrations of most molecules were
concentrations were taken into consideration. only covered by one reference (N 67). For 22 molecules,
A search was made to register a representative mean two references were used.
or median normal concentration, a representative mean In addition, if available, the single highest uremic con-
centration ever reported was illustrated as well (CMAX).or median uremic concentration, and the highest reported
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This information was not necessarily obtained from the cules) were compared statistically to each other by the
Mann-Whitney U test. Dichotomous variables weresame publication as the mean/median uremic value. If no
range or individual values could be found, a hypothetical compared by chi-square test. Statistical significance was
accepted for P  0.05.maximal value was calculated as:
CMAX  Mean  2 SD (Eq. 3)
RESULTS
Finally, the number of patients on which the CN and
The concentrations of in total 90 uremic solutes areCU values had been obtained, the molecular weight, the
listed in Tables 1 to 3. In Table 1, results regarding 45reference(s) from which the data had been collected, and
low molecular weight solutes (molecular weight 500 D)(if available) the larger group to which the molecules be-
without known protein binding (small free water-solublelonged (e.g., guanidines, phenols, peptides) were reported.
compounds) are summarized [12–33]. Similarly, Table 2Molecules were subdivided into three major classes:
contains data on 25 compounds with known protein bind-(1) small solutes (500 D) with no known protein bind-
ing or belonging to groups of solutes that are known to being; (2) solutes with known or likely protein binding;
protein bound [10, 11, 20, 34–53]. Most of these protein-and (3) middle molecules (500 D). For all the protein-
bound solutes are also characterized by a molecular weightbound solutes, only the total concentrations were illus-
500 D, although two of these compounds (leptin andtrated.
retinol-binding protein) have a molecular weight conform-The lower cutoff value for the so-called middle mole-
ing with that of the middle molecules. For these protein-cules (500 D) was based on the original literature data
bound compounds, the tables only contain total (free reporting on this class of uremic solutes [6]. In this litera-
bound) concentrations. Table 3 then contains informa-ture, middle molecule molecular weight range is usually
tion on the middle molecules (N  22) [22, 45, 53–66].reported as 500 to 2000 D. Since most of the identified
Hence, 68 solutes are characterized by a molecularlarger uremic solutes are characterized by a molecular
weight below 500 D. Among the 22 middle molecules,weight in excess of 2000 D, the upper limit for middle
12 (54.5%) have a molecular weight 	12,000 D.molecules was not restricted to 2000 D, but all solutes
For several molecules, we found a discordance betweenwith a molecular weight in excess of 2000 D were also
the highest [13, 34, 63] and the lowest range of reportedenlisted as middle molecules.
uremic concentrations [15, 36, 67]. The most strikingMolecules that are not filterable through the glomeru-
examples [asymmetric dimethylarginine (ADMA); in-lar basement membrane because of their molecular size
terleukin-6 (IL-6); 3-deoxyglucosone (3-DG)] are illus-(molecular weight	60,000 D) were not included [e.g.,
trated in Table 4, where, in each instance, a discrepancylipoprotein(a)]. Likewise, anorganic compounds were
by a factor of 8 or more was observed. In Tables 1 to 3excluded, although it is acknowledged that they can exert
only the highest reported value is illustrated. It is of notetoxicity (e.g., H2O, K, phosphate, trace elements). The
that for ADMA, values intermediate between the lowerreader is referred for these compounds to specific publi-
range as observed by Marescau et al [15] and the highercations [7–9].
range observed by Kang et al [13] have been reportedFurthermore, the ratio between mean uremic and nor-
by Vallance et al [14] (approximately 878.5 g/L) andmal concentration was calculated (CU/CN) to obtain an
Zoccali et al [68] (777.7 g/L).index of the relative increase during uremia. In addition,
The uremic concentration of the 90 reported mole-also the ratio of maximal over mean uremic concentra-
cules was spread over a broad range, from 2.3 g/L [urea,tion (CMAX /CU) was calculated. The latter index describes
full urea concentration; for blood urea nitrogen (BUN)whether data distribution was Gaussian or not.
multiply by 28/60] to 32.2 ng/L (methionine-enkephalin)For some of the advanced glycation end products
(factor	70 104). The concentration range for the small(AGEs), published concentrations are expressed in the
water-soluble compounds (N 45) extended from 2.3 g/Lliterature as picogram per milligram (pg/mg) protein or
(urea) to 62.7 ng/L (
-lipotropin) (Table 1). The rangemicrogram per milligram (g/mg) protein [10, 11]. Since
for the protein-bound solutes (N  25) extended fromin these publications, however, no serum total protein
247.0 mg/L (hippuric acid) to 175.8 ng/L (melatonin)was mentioned, it was impossible to extrapolate the abso-
(Table 2), and for the middle molecules (N  22) fromlute AGE concentrations. In these cases, absolute con-
192.0 mg/L (retinal-binding protein) to 32.2 ng/L (methi-tent was calculated by multiplying with an average serum
onine-enkephalin) (Table 3) The median concentrationprotein concentration (i.e., 70,000 mg/L). The reported
value was 773.8 g/L overall (methylguanidine) and wasAGE values all were obtained in uremic patient groups
1.2 mg/L for the small water-soluble compounds, as wellwithout diabetes mellitus.
as for the protein-bound compounds, but only 0.95 g/LFor statistical comparison, an Instat statistical pack-
for the middle molecules. Considering these medians, inage was used. Sets of values reported per group of mole-
cules (small water-soluble, protein-bound, middle mole- general, the concentration of the middle molecules was
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Table 1. Free water-soluble low-molecular-weight solutes (N  45)
Solute CN CU CMAX MW Ref Group
1-methyladenosine lg/L 17.15.1/10 104.056.2/17 216.4 281 [12] Ribonucleosides
1-methylguanosine lg/L 13.716.9/10 41.623.8/17 89.2 297 [12] Ribonucleosides
1-methylinosine lg/L 13.53.9/10 620.4203.4/14 1027.2 282 [12] Ribonucleosides
ADMA mg/L 0.20.06/6 1.61.2/10 7.3a 202 [13, 14] Guanidines
-keto--guanidinovaleric acid lg/L 30.2/66 — 140.4a 151 [15] Guanidines
-N-acetylarginine lg/L 18.124.8/16 328.3142.6/13 4580.0a 216 [16, 17] Guanidines
Arab(in)itol mg/L 0.6/33 15.09.0/12 33.0 152 [18, 19] Polyols
Argininic acid lg/L 77.0/66 80.556.0/11 197.8a 175 [15, 16] Guanidines
Benzylalcohol mg/L — 27.050.7/17 187.9a 108 [20]

-guanidinopropionic acid lg/L 3.3/24 28.818.3/29 65.4 131 [21] Guanidines

-lipotropin ng/L 55.3/10 62.7/22 108.8a 461 [22] Peptides
Creatine mg/L 9.73.3/24 134.030.3/29 235.8a 131 [21] Guanidines
Creatinine mg/L 12.0/23 136.046.0/19746 240.0a 113 [23, 24] Guanidines
Cytidine lg/L 468.0 683.3287.8/7 1263.6a 234 [25] Purines
Dimethylglycine lg/L 381.1/33 576.8/18 1040.3a 103 [26]
Erythritol mg/L 0.7/33 9.814.0/12 37.0a 122 [18, 19] Polyols
-guanidinobutyric acid lg/L 3.6/24 33.316.0/30 1750.0a 145 [27, 17] Guanidines
Guanidine lg/L 11.8/16 172.983.8/13 800.0a 59 [16, 17] Guanidines
Guanidinoacetic acid lg/L 222.379.6/24 383.8143.9/29 693.8a 117 [21] Guanidines
Guanidonosuccinic acid mg/L 0.030.01/16 6.53.4/13 47.0a 175 [16, 17] Guanidines
Hypoxanthine mg/L 1.50.5/145 2.01.6/65 5.3 136 [28, 29] Purines
Malondialdehyde lg/L 257.781.7/30 428.8170.4/16 769.6 71 [30]
Mannitol mg/L 1.3/33 26.025.0/12 76.0 182 [18, 19] Polyols
Methylguanidine lg/L 7.3/24 773.8508.8/5 1820.0a 73 [21, 17] Guanidines
Myoinositol mg/L 10.0/8 94.069.0/12 232.0 180 [18] Polyols
N2,N2-dimethylguanosine lg/L 9.04.7/10 236.489.7/14 415.8 311 [12] Ribonucleosides
N4-acetylcytidine lg/L 57.017.1/10 159.630.8/14 221.2 285 [12] Ribonucleosides
N6-methyladenosine lg/L 18.58.4/10 70.353.3/17 176.9 281 [12] Ribonucleosides
N6-threonylcarbamoyladenosine lg/L 35.527.2/10 378.0151.2/17 680.4 378 [12] Ribonucleosides
Orotic acid mg/L 0.51.4/30 6.716.0/22 38.7 174 [31] Pyrimidines
Orotidine mg/L 1.21.6/30 20.213.5/22 47.2 288 [31] Pyrimidines
Oxalate mg/L 0.30.1/8 4.91.4/8 7.6 90 [32]
Phenylacetylglutamine mg/L 4.7 53.344.7/6 120.6a 264 [33]
Pseudouridine mg/L 0.55.8/30 13.121.4/7 86.6a 244 [25, 31] Ribonucleosides
SDMA lg/L 76.121.0/66 640.3212.1/38 1232.2a 202 [15] Guanidines
Sorbitol mg/L 0.4/33 3.12.1/12 7.3 182 [18, 19] Polyols
Taurocyamine lg/L 52.2/24 — 121.8a 174 [17] Guanidines
Threitol lg/L 319.6/33 990.0920.0/12 5697.4a 122 [18, 19] Polyols
Thymine mg/L — 2.84.2/22 11.2 126 [31] Pyrimidines
Uracil lg/L 224.0 252.0154.6/7 448.0a 112 [25] Purines
Urea g/L 0.4/23 2.31.1/16 4.6a 60 [24]
Uric acid mg/L 67.2 83.444.5/7 146.7a 168 [25] Purines
Uridine mg/L 1.51.3/30 9.811.4/22 32.6 244 [31] Pyrimidines
Xanthine mg/L 0.51.4/180 1.50.8/65 3.0 152 [28, 29] Purines
Xanthosine lg/L 23.912.8/10 96.662.9/11 222.4 284 [12] Ribonucleosides
Abbreviations are: CN, normal concentration; CU, mean/median uremic concentration; CMAX, maximal uremic concentration; MW, molecular weight; ref, reference;
ADMA, asymmetrical dimethylarginine; SDMA, symmetrical dimethylarginine. The underlined numbers behind the slash point to the number of data on which the
means or medians have been obtained. No underlined number indicates that no data about the number of samples were available. Normal values are reported as
meansSD, or in the case of a single value as a maximum (accompanied by ); uremic values are reported as meansSD or, in the case of a single value, as a
median.
aCMAX values are original data (all other values were calculated as mean  2 SD based on CU)
lower compared to the water-soluble and protein-bound are listed in Table 5. The cutoff values for these lists
were set arbitrarily. Among the eight compounds withsolutes and this was confirmed by comparative statistical
analysis (P  0.01 vs. small water-soluble compounds; the highest CU/CN index, there were two guanidines, three
protein-bound solutes, and two middle molecules. AmongP  0.02 vs. protein-bound compounds). For 10 out of
22 of the middle molecules (45.5%) uremic concentra- the 20 lowest scoring compounds, there were seven mid-
dle molecules. When considering the index per group oftion was in ng/L range, compared with 1 out of 45 small
water-soluble compounds (2.2%; P  0.001) and 1 out molecules, only the difference between protein-bound
molecules and middle molecules was at the borderlineof 25 protein-bound compounds (2.5%; P  0.01).
The index CU/CN offers an indication about the differ- of significance (P  0.06).
The index CMAX/CU indicates which solutes show a non-ences between uremic and normal concentration values,
over which toxicity can be exerted. The 20 solutes scoring Gaussian distribution, in a way that the highest ratios
are obtained for the solutes with the most abnormalhigher than 15 and the 19 solutes scoring lower than 2.5
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Table 2. Protein-bound solutes (N  25)
Solute CN CU CMAX MW Ref Group
2-methoxyresorcinol lg/L — 19.681.2/17 322.0a 140 [20] Phenols
3-deoxyglucosone mg/L 0.30.1/30 1.71.0/27 3.5 162 [34] AGE
CMPF mg/L 7.73.3/7 61.016.5/15 94.0a 240 [35]
Fructoselysine mg/L — 58.110.8/10 79.7 308 [10] AGE
Glyoxal lg/L 67.020.0 221.028.0/20 277.0 58 [36] AGE
Hippuric acid mg/L 5.0 247.0112.0/7 471.0 179 [37] Hippurates
Homocysteine mg/L 1.7/24 8.11.6/7 26.4a 135 [38–40]
Hydroquinone lg/L — 50.684.7/17 286.0a 110 [20] Phenols
Indole-3-acetic acid lg/L 17.517.5/7 875.0560.0/42 9076.9a 175 [41,42] Indoles
Indoxyl sulfate mg/L 0.65.4/40 53.091.5/20 236.0 251 [35] Indoles
Kinurenine lg/L 391/7 686.4178.9/21 952.6 208 [43] Indoles
Kynurenic acid mg/L 1.0 — 9.5a 189 [44] Indoles
Leptin lg/L 8.46.7/56 72.060.6/8 490.0a 16000 [45, 46] Peptides
Melatonin ng/L 26.57.1/35 175.8130.2/13 436.2 126 [47] Indoles
Methylglyoxal lg/L 47.012.0/15 110.018.0/20 146.0 72 [36] AGE
Nε–(carboxymethyl)lysine mg/L 1.10.3/24 4.31.3/44 6.9 204 [11] AGE
p-cresol mg/L 0.61.0/12 20.110.3/20 40.7 108 [48] Phenols
Pentosidine lg/L 51.618.8/19 896.0448.0/24 2964.0a 342 [49] AGE
Phenol mg/L 0.60.2/12 2.73.9/10 10.5 94 [48] Phenols
P-OHhippuric axid mg/L — 18.36.6/13 31.5 195 [50] Hippurates
Putrescine lg/L 21.17.9/10 77.427.3/25 132.0 88 [51] Polyamines
Quinolinic acid mg/L 0.10.05/10 1.50.9/54 3.3 167 [52] Indoles
Retinol-binding protein mg/L 80 192.078.0/112 369.2a 21200 [53] Peptides
Spermidine lg/L — 97.245.0/25 187.2 145 [51] Polyamines
Spermine lg/L — 18.216.2/25 66.7a 202 [51] Polyamines
Abbreviations are: CN, normal concentration; CU, mean/median uremic concentration; CMAX, maximal uremic concentration; MW, molecular weight; ref, reference;
CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; AGE, advanced glycation end products. The underlined numbers behind the slash point to the number
of data on which the means or medians have been obtained. No underlined number indicates that no data about the number of samples were available. Normal
values are reported as meansSD, or in the case of a single value as a maximum (accompanied by ); uremic values are reported as meansSD.
aCMAX values are original data (all other values were calculated as mean  2 SD based on CU).
Table 3. Middle molecules (N  22)
Solute CN CU CMAX MW Ref Group
Adrenomedullin ng/L 13.24.6/17 41.819.7/29 81.2 5729 [54] Peptides
Atrial natriuretic peptide ng/L 28.012.2/23 202.0117.3/27 436.6 3080 [55] Peptides

2-microglobulin mg/L 2.0 55.07.9/10 100.0a 11818 [53, 56] Peptides

-endorphin ng/L 173.3/10 301.5/22 492.0a 3465 [22] Peptides
Cholecystokinin ng/L 20.0 45.932.3/38 131.5a 3866 [57] Peptides
Clara cell protein (CC16) mg/L 0.1 3.32.0/112 12.5a 15800 [53] Peptides
Complement factor D mg/L 1.90.5/5 19.84.1/5 26.0a 23750 [58]
Cystatin C mg/L 1.6 11.83.0/112 20.0a 13300 [53] Peptides
Degranulation inhibiting protein Ic lg/L 321.759.7/23 713.7390.0/125 1631.4a 14100 [59]b Peptides
Delta-sleep inducing peptide lg/L — 1.50.9/7 3.3 848 [60] Peptides
Endothelin ng/L 20.83.8/23 63.033.2/12 129.4 4283 [55] Peptides
Hyaluronic acid lg/L 124.0/86 215.0257.0/184 1843.0a 25000 [61] Peptides
Interleukin-1
 ng/L 160.0/15 428.0134.0/29 1700.0 32000 [62] Cytokines
Interleukin-6 ng/L 13.33.1/28 92.3117.9/230 328.1 24500 [63] Cytokines
-Ig light chain mg/L 34.015.0/15 70.060.9/104 287.0a 25000 [64] Peptides
-Ig light chain mg/L 31.011.2/15 87.060.9/104 328.0a 25000 [64] Peptides
Leptin lg/L 8.46.7/56 72.060.6/8 490.0a 16000 [45, 46] Peptides
Methionine-enkephalin ng/L 18.3/10 32.2/22 75.5a 555 [22] Peptides
Neuropeptide Y ng/L 80.0 64.925.5/19 115.9 4272 [57] Peptides
Parathyroid hormone lg/L 0.06 1.20.6/10 2.4 9225 [65] Peptides
Retinol-binding protein mg/L 80 192.078.0/112 369.2a 21200 [53] Peptides
Tumor necrosis factor- ng/L 13.33.0/28 114.0147.0/230 408.0 26000 [63, 66] Cytokines
Abbreviations are: CN, normal concentration; CU, mean/median uremic concentration; CMAX, maximal uremic concentration; MW, molecular weight; ref, reference.
The underlined numbers behind the slash point to the number of data on which the means or medians have been obtained. No underlined number indicates that
no data about the number of samples were available. No number indicates that no n value was given. Normal values are reported as mean  SD, or in the case of
a single value as a maximum (accompanied by ); uremic values are reported as mean  SD or, in the case of a single value, as a median.
a CMAX values are original data (all other values were calculated as mean  2 SD based on CU)
b S Schmaldienst, Vienna: personal communication
c Degranulation inhibiting protein I corresponds to angiogenin
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Table 4. Highest versus lowest reported concentrations
Low range CU Ref High range CU Ref Low range CMAX Ref High range CMAX Ref
ADMA lg/L 169.531.2 [15] 1616.01212.0 [13] 282.8 [15] 7272.0 [13]
IL-6 ng/L 11.72.8 [67] 92.3117.9 [63] 80.0 [67] 328.1 [63]
3-DG lg/L 59.013.0 [36] 1715.01009.6 [34] 85.0 [36] 3500 [34]
Abbreviations are: CU, mean/median uremic concentration; CMAX, maximal uremic concentration; ADMA, asymmetrical dimethylarginine; IL-6, interleukin-6;
3-D6, 3-deoxyglucose.
Table 5. CU/CN ratio: Highest and lowest scoring molecules Table 7. Solutes to be considered for the future
20 solutes scoring 15 19 solutes scoring 2.5 1-alkyl-2-formyl-3,4-glycosyl-pyrrole
2-(2-fuoryl)-4(5)-(2-furanyl)-1H-imidazole
Guanidinosuccinic acid 216.67 Retinol-binding protein 2.40a 3-deoxyfructosone
Methylguanidine 106.00a Methylglyoxal 2.34 3-hydroxykinurenine
Indoxyl sulfate 88.33 Cholecystokinin 2.30a 4-hydroxynonenal
Indole-3-acetic acid 50.00 3-deoxyglucosone 2.27 Advanced oxidation protein products (AOPP)
Hippuric acid 49.40a Degranulation inhibiting Advanced glycation end products-
2-microglobulin1-methylinosine 45.96 protein I 2.21 Anthranilic acid
p-cresol 33.50 -Ig light chain 2.20

2-microglobulin fragmentsClara cell protein (CC16) 33.00a Methionine-enkephalin 1.76a Cadaverine

2-microglobulin 27.50a Kinurenine 1.76a Crossline
N2,N2-dimethylguanosine 26.27 ADMA 1.75 Dimethylamine
Pseudouridine 26.20 ß-endorphin 1.74a Guanosine
Arab(in)itol 25.00a Hyaluronic acid 1.73a Imidazolone
Parathyroid hormone 20.00a Guanidinoacetic acid 1.73 Malonaldehyde
Mannitol 20.00a Dimethylglycine 1.51a Malondialdehyde
Interleukin-6 19.50 Cytidine 1.46a Methylamine
-N-acetylarginine 18.14 Hypoxanthine 1.33 Nε-carboxyethyllysine
Pentosidine 17.36 Uric acid 1.24a Organic chloramines
Orotidine 16.83 
-Lipotropin 1.13a Oxidized low-density-lipoprotein (oxLDL)
Oxalate 16.33 Argininic acid 1.05a Parathyroid hormone fragments
Quinolinic acid 15.00 Neuropeptide Y 0.81a Pyrraline
Pyrrole aldehydeAbbreviations are: CU, mean/median uremic concentration; CN, normal con-
centration; ADMA, asymmetrical dimethylarginine. The cut-off values of 15 and Trimethylamine
2.5 were set arbitrarily. Solutes with a high score display a high differential
concentration, uremic vs. normal, over which biologic activity (toxicity) can be
exerted. Conversely, this range is limited for solutes displaying a low value.
aCU/CN obtained with CN as a maximal (not as a mean) value
exactly known and/or because their uremic retention has
not been proven.
Table 6. CMAX/CU ratio: Highest scoring molecules
-Guanidinobutyric acid 52.55 Pseudouridine 6.61 DISCUSSION
2-Methoxyresorcinol 16.43 Oxalate 6.55
This literature search essentially offers an overview of-N-acetylarginine 13.95 Orotic acid 5.78
Indole-3-acetic acid 10.37 Threitol 5.75 the currently known uremic retention solutes, together
Hyaluronic acid 8.57 Hydroquinone 5.65 with their reported concentrations. Furthermore, a num-
Guanidinosuccinic acid 7.23 Guanidine 4.63
ber of physicochemical characteristics and relative differ-Benzylalcohol 6.96 Indoxyl sulfate 4.45
Interleukin-6 6.84 Erythreitol 4.11 ences between uremic and normal concentrations and
Leptin 6.81 Thymine 4.00 between maximal and mean uremic concentrations are
Abbreviations are: CMAX, maximal uremic concentration; CU, mean/median considered as well.
uremic concentration.
The resulting lists are a striking illustration of the
complexity of uremic retention. Obviously, there is more
than the retention of a single compound or even a group
of compounds, and also, there is more than the retentiondistribution. In Table 6, the compounds with a CMAX/CU
above or equal to 4.0 are displayed. It contains 17 com- of the current markers, urea and creatinine. Without any
doubt, clinical uremic toxicity is even more complex,pounds, four of which are guanidines, but also some
middle molecules, such as leptin (6.81), IL-6 (6.84), and since a host of retained compounds remain unidentified.
In the present inventory, uremic solutes are listed andhyaluronic acid (8.57) are included. We found no statisti-
cally significant differences among groups. classified according to the characteristics that potentially
influence their removal pattern during dialysis or otherFinally, in Table 7, a number of molecules to be consid-
ered for the future are listed. They do not figure in Tables methods of extracorporeal elimination (i.e., molecular
weight and lipophilicity/hydrophilicity resulting in pro-1 to 3 because either their uremic concentration is not
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tein binding). The publication does not deal with bio- ture and, hence, also its binding capacity for other ligands
[80]. Nevertheless, the relation with the binding proteinschemical or clinical relevance of the listed compounds,
which has been presented by the same group of authors is probably different from that of other classical protein-
bound solutes, such as indoxyl sulfate or p-cresol. Theelsewhere [3]. The major practical impact of this work
is as a tool for the future for any effort of in vitro or binding should be considered as more long-lived than
for the other ligands, which display a continuous andin vivo evaluation of uremic toxicity. Furthermore, the
information collected here might also be of help for dynamic competition among each other and with drugs
for the protein-binding sites [81–83]. In some publications,kinetic evaluation and modeling of uremic toxin time
courses for generation rate and their appearance in dif- not only total concentrations but also free concentrations
are reported for the AGEs [11, 56]. These values are byferent compartments.
Our data clarify the need to approach the problem of definition much lower than the total concentration. More
than 250-fold lower values were found for furosine, theuremic toxicity in a different way than has been done in
the past, as analyses were essentially restricted to the free fraction of fructoselysine (201.1 73.1g/L vs. 58.1
10.8 mg/L) [11]. The tables only contain total (free evaluation of one or a few molecules regarding their
impact on one or a few biologic systems. The consider- bound) concentrations.
One should be aware of the fact that the biologication of several compounds or groups of compounds at
a time might conform more with reality. Hence, to solve action of protein-bound compounds is exerted by their
free fraction. Hence, the total concentrations, as depictedthe problem of uremic toxicity, collaborative studies in-
volving different research groups with different scopes in the present tables, are only valid if the experimental
medium contains a sufficient quantity of albumin (orof interest will be needed. Another aspect to be consid-
ered for the future is the intermutual interference of plasma protein). For in vitro experiments, it might be
worthwhile to measure the free fraction in the final me-uremic compounds, which might necessitate the study
of solutes in a “uremic” rather than a “normal” milieu. dium; however, usually only one solute will be added at
a time, whereas in vivo many ligands will be presentIt is of note that molecules with a molecular weight
exceeding 60,000 D (cutoff of the glomerular basement together, competing for the protein-binding sites and
increasing the free fraction.membrane) and anorganic substances were excluded
from the analysis. This, for example, eliminated lipopro- Overall, molecular weights of the listed compounds
extended from 60 D (urea) to 32,000 D (IL-1
). Alsotein (a) (molecular weight 100,000 D), despite an en-
hanced concentration in uremia [69, 70], and a potential concentrations extended over a broad range with as high-
est value urea, in the g/L range, and as the lowest methio-for biologic activity. Likewise, phosphate was excluded,
despite a potential link to cardiovascular morbidity/mor- nine-enkephalin, in the ng/L range. A high concentration
is not necessarily related to a strong biologic activity.tality [9, 71].
Essentially, we discerned small water-soluble com- The two molecules with the highest concentrations (urea
and creatinine) are known for their relatively limitedpounds with a low molecular weight (500 D), small
protein-bound solutes, and middle molecules (500 D). biologic activity [1, 3]. Addition of urea to the dialysate
at concentrations exceeding those encountered in uremiaThe two latter types of molecules are characterized by
a reduced removal during standard dialysis with small had relatively little impact on the clinical status of the
patients submitted to this regimen [84].pore, low-flux membranes [72, 73], compared to the small
water-soluble compounds. Although not definitely con- The index CU/CN offers an indication on the differences
between uremic and normal values. The larger the gapclusive, circumstantial evidence suggests that membranes
with a larger pore size are not only linked to a more effi- between the two values, and the larger the index, the
larger the range over which biologic activity can be ex-cient removal of larger molecules [73–75], but also to an
improvement of clinical status and/or survival [4, 76–78]. erted, and the bigger the chance that biologic effects
become apparent in vivo or in vitro. It is of note that aIt is of note that a recent prospective study could not
demonstrate, however, any difference in survival out- high CU/CN is to a large extent characteristic of guani-
dines, protein-bound solutes, and middle molecules (al-come in patients treated with large pore vs. small pore
dialyzers [79]. together 13/20 of the solutes scoring	15), whereas many
of these compounds exert substantial biologic activityProtein-bound molecules, on the other hand, are not
very efficiently removed by any dialytic procedure [72]. [1, 3]. Furthermore, all these molecules are characterized
by a different intradialytic behavior compared to theAs a consequence, their concentration can hardly be
influenced in ESRD, so that their clinical impact could classical marker urea [27, 72, 73].
For protein-bound molecules the ratio CU/CN mightnever be studied appropriately in dialyzed uremics.
AGEs were classified among the protein-bound sol- even become more important for the unbound and bio-
logically active fraction, than for total concentration, asutes. AGEs have been shown to be bound to albumin
and other proteins and may even change albumin struc- has been observed for p-cresol [85].
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Hence, removal strategies should be designed in a way different mean uremic or highest values than the ones
that not only the standard molecules, but also other reported here. For that matter, this database will need
molecules that might be more important in the deteriora- continuous updating (see Acknowledgments). Neverthe-
tion of the clinical condition, can be removed efficiently. less, the present data offer, in our opinion, a broad over-
A typical example is cardiovascular morbidity and mor- view of the present state of the art, and such an overview
tality, at present one of the most worrying complications has, to our knowledge, never been published before. The
of the uremic condition [3]. Careful analysis of the litera- authors will appreciate receiving additional information
ture shows that most molecules held as yet responsible about new solutes to be added to the lists, or about
for uremic toxicity are removed in a different way than enlisted molecules with reported concentrations that are
urea and creatinine, either due to their molecular weight, different from the ones that are cited at present, enabling
protein binding, and/or multicompartmental behavior a continuous update.
[1, 3]. Subsequently, dialytic removal strategies should
be adapted accordingly, based on a global knowledge of
CONCLUSIONthe compounds playing a role in any complication of
An overview is given on the reported range of concen-uremia.
tration of uremic retention solutes. Most known uremicThe index CMAX/CU indicates which solutes follow a
retention solutes have a low molecular weight, althoughnon-Gaussian distribution. The higher the value of this
these not necessarily exert toxicity, especially if theyindex, the more abnormal the distribution of concentra-
are not protein bound. Concentrations of 90 solutes aretions. This might be the consequence of various interfer-
reported, ranging from 2.3 g/L (urea) to 0.32 ng/L (methi-ing factors that are not necessarily related to the uremic
status (e.g., gender, genetic predisposition, general con- onine-enkephalin). Low concentrations are found espe-
dition, body composition, or nutritional status) [46, 86– cially for the middle molecules. The ratio CU/CN is high
88]. Several guanidines and middle molecules show a for several of the guanidines, protein-bound molecules,
strong trend for abnormal distribution. Among these, and middle molecules, and many of these solutes are
IL-6 and leptin may have an important potential for toxic. These data can be of use as a guideline for future
biologic activity [3]. in vivo and in vitro experiments. Uremic retention ap-
It is of note that for certain solutes a substantial gap pears to be a complex kinetic and multifactorial problem
exists between the highest reported mean concentrations concerning a larger amount of solutes than those cur-
[13, 34, 63] and the other reported concentrations [15, rently used as markers, such as urea and creatinine.
36, 67]. This is the case for ADMA, IL-6, and 3-DG
(Table 4). We considered it beyond the scope of this ACKNOWLEDGMENTS
work to offer a critical analysis on the origin(s) of these
The European Uremic Toxin Work Group (EUTox) has been cre-
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mic retention solutes. More information about the European Uremicif in chromatographic analysis [e.g., high-performance Toxin Work Group, which is responsible for this publication, can be
liquid chromatography (HPLC)] peak heights are over- obtained at the website: http://uremic-toxins.org.
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